- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07476287
Symbiotic-Lung-14: Een onderzoek naar de studie-medicatie PF08634404 in combinatie met chemotherapie bij volwassen deelnemers met getransformeerd kleincellig longcarcinoom
EEN INTERVENTIONEEL FASE 2-ONDERZOEK NAAR PF-08634404 IN COMBINATIE MET CHEMOTHERAPIE BIJ DEELNEMERS MET VOORAF NIET BEHANDELD GETRANSFORMEERD KLEINCELLIG LONGCARCINOOM
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working.
To join the study, participants must meet the following conditions:
- Are aged 18 years or older
- Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted)
- Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs)
- Have healthy organs based on medical tests and are in good physical condition
After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Pfizer CT.gov Call Center
- Telefoonnummer: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studie Locaties
-
-
New South Wales
-
Westmead, New South Wales, Australië, 2145
- Nog niet aan het werven
- Westmead Hospital
-
-
South Australia
-
Elizabeth Vale, South Australia, Australië, 5112
- Werving
- Calvary Connery Centre
-
-
Victoria
-
Heidelberg, Victoria, Australië, 3084
- Nog niet aan het werven
- Warringal Private Hospital
-
-
-
-
-
Porto Alegre, Brazilië, 90610-000
- Werving
- Hospital São Lucas da PUCRS
-
São Paulo, Brazilië, 01452-000
- Nog niet aan het werven
- Centro Paulista de Oncologia Clínica
-
-
São Paulo
-
São Paulo, São Paulo, Brazilië, 01321-001
- Werving
- Hospital Beneficência Portuguesa de São Paulo
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Werving
- Peking Union Medical College Hospital
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Werving
- Fujian Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Werving
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430048
- Werving
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330200
- Werving
- The First Affiliated Hospital of Nanchang University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200030
- Werving
- Shanghai Chest Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Werving
- The first Affiliated Hospital, Zhejiang University School of Medicine
-
-
-
-
-
Lyon, Frankrijk, 69373
- Werving
- Centre Léon Bérard
-
Marseille, Frankrijk, 13915
- Werving
- Assistance Publique Hôpitaux de Marseille - Hôpital Nord
-
Villejuif, Frankrijk, 94805
- Nog niet aan het werven
- Institut Gustave Roussy
-
-
-
-
-
Hong Kong, Hongkong
- Werving
- Queen Mary Hospital
-
Hong Kong, Hongkong
- Werving
- Prince of Wales Hospital
-
-
-
-
Kerala
-
Kottayam, Kerala, Indië, 686630
- Werving
- Caritas Hospital and Institute of Health Sciences
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indië, 110085
- Werving
- Rajiv Gandhi Cancer Institute And Research Centre
-
-
-
-
HA Merkaz
-
Ramat Gan, HA Merkaz, Israël, 5265601
- Werving
- Sheba Medical Center
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israël, 9103102
- Werving
- Shaare Zedek Medical Center
-
-
-
-
-
Bergamo, Italië, 24125
- Werving
- Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni
-
-
ROME
-
Roma, ROME, Italië, 00144
- Nog niet aan het werven
- IRCCS Istituto Nazionale dei Tumori Regina Elena
-
-
Turin
-
Orbassano, Turin, Italië, 10043
- Werving
- A.O.U. San Luigi Gonzaga
-
-
-
-
-
Osaka, Japan, 541-8567
- Werving
- Osaka International Cancer Institute(OICI)
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Werving
- Aichi Cancer Center Hospital
-
-
Okayama-ken
-
Kita, Okayama-ken, Japan, 700-8558
- Nog niet aan het werven
- Okayama University Hospital
-
-
Osaka
-
Hirakata, Osaka, Japan, 573-1191
- Werving
- Kansai Medical University Hospital
-
-
Tokyo
-
Chūō, Tokyo, Japan, 104-0045
- Werving
- National Cancer Center - Tsukiji Campus
-
Kotoku, Tokyo, Japan, 135-8550
- Werving
- Japanese Foundation for Cancer Research
-
-
-
-
-
Madrid, Spanje, 28041
- Werving
- Hospital Universitario 12 de Octubre
-
Seville, Spanje, 41013
- Werving
- Hospital Universitario Virgen Del Rocio
-
-
Catalunya [cataluña]
-
L'Hospitalet de Llobregat, Catalunya [cataluña], Spanje, 08908
- Werving
- Institut Català d'Oncologia - L'Hospitalet
-
-
-
-
-
Tainan, Taiwan, 704302
- Werving
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 100
- Werving
- National Taiwan University Hospital
-
Taipei, Taiwan, 11217
- Werving
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 106
- Werving
- National Taiwan University Cancer Center (NTUCC)
-
-
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- Werving
- City of Hope National Medical Center
-
Encinitas, California, Verenigde Staten, 92024
- Werving
- UC San Diego Medical Center - Encinitas
-
Irvine, California, Verenigde Staten, 92618
- Werving
- City of Hope Lennar Foundation Cancer Center
-
La Jolla, California, Verenigde Staten, 92037
- Werving
- UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
-
La Jolla, California, Verenigde Staten, 92037
- Werving
- UC San Diego Sulpizio Cardiovascular Center
-
La Jolla, California, Verenigde Staten, 92037
- Werving
- UC San Diego Moores Cancer Center
-
La Jolla, California, Verenigde Staten, 92037
- Werving
- UC San Diego Koman Family Outpatient Pavilion
-
San Diego, California, Verenigde Staten, 92101
- Werving
- UC San Diego Medical Center - Bankers Hill
-
San Diego, California, Verenigde Staten, 92103
- Werving
- UC San Diego McGrath Outpatient Pavilion - Hillcrest
-
San Diego, California, Verenigde Staten, 92127
- Werving
- UC San Diego Medical Center - Rancho Bernardo
-
San Diego, California, Verenigde Staten, 92103
- Werving
- UC San Diego Medical Center- Hillcrest
-
Vista, California, Verenigde Staten, 92081
- Werving
- UC San Diego Medical Center - Vista
-
-
Illinois
-
Hinsdale, Illinois, Verenigde Staten, 60521
- Werving
- Hope and Healing Clinical Research
-
New Lenox, Illinois, Verenigde Staten, 60451
- Werving
- Hope and Healing Clinical Research
-
-
New Jersey
-
Basking Ridge, New Jersey, Verenigde Staten, 07920
- Werving
- MSK Basking Ridge
-
Middletown, New Jersey, Verenigde Staten, 07748
- Werving
- MSK Monmouth
-
Montvale, New Jersey, Verenigde Staten, 07645
- Werving
- MSK Bergen.
-
-
New York
-
Commack, New York, Verenigde Staten, 11725
- Werving
- MSK Commack
-
Harrison, New York, Verenigde Staten, 10604
- Werving
- MSK Westchester
-
Long Island City, New York, Verenigde Staten, 11101
- Werving
- Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
-
New York, New York, Verenigde Staten, 10065
- Werving
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Verenigde Staten, 10021
- Werving
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
-
Uniondale, New York, Verenigde Staten, 11553
- Werving
- MSK Nassau
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male or female participants aged ≥18 years at the time of informed consent.
- Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).
- Participants have not received systemic therapy for T-SCLC.
- Have at least one measurable lesion as the target lesion based on RECIST v1.1.
- Have sufficient tumor tissue from the diagnosis of transformed SCLC available.
- Eastern Cooperative Oncology Group performance status of 0 or 1.
- Have a minimum life expectancy of >12 weeks.
- Clinical laboratory values at screening within acceptable limits, as defined in the protocol, including: 1) Hematology, 2) Liver function and 3) Renal function.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
-
Active or untreated CNS disease, including brain, brainstem, spinal cord, or meningeal metastases. Participants with definitively treated, clinically stable brain metastases may be eligible per protocol criteria. Participants with untreated asymptomatic brain metastases of longest diameter <1 cm are permitted if all of the following criteria are met: absence of neurological symptoms, no need for corticosteroids, and brain metastasis has no evidence of edema or hemorrhagic features.
-
Leptomeningeal disease
-
Clinically significant risk of hemorrhage or fistula, including tumor necrosis/cavitation, invasion or compression of major blood vessels, airways, or critical organs, or risk of tracheoesophageal or pleuroesophageal fistula
-
History of another malignancy (other than NSCLC) within 3 years prior to first dose, except for malignancies with negligible risk of metastasis or death (eg, adequately treated carcinoma in situ, nonmelanoma skin cancer)
-
Unresolved toxicity from prior anti-tumor therapy that has not recovered to Grade ≤1 per NCI CTCAE v5.0 (except alopecia or irreversible toxicities deemed stable)
-
History of allogeneic organ or hematopoietic stem cell transplantation
-
Active autoimmune disease requiring systemic treatment within the past 2 years (Stable replacement therapy and selected low-risk autoimmune conditions are permitted per protocol)
-
Interstitial lung disease (ILD), pneumonitis, or significant pulmonary disease, including:
- Prior or current non-infectious pneumonitis requiring systemic therapy
- DLCO <50% predicted
- Severe asthma, COPD, pulmonary embolism, or autoimmune lung involvement
-
Uncontrolled or clinically significant cardiovascular, cerebrovascular, metabolic, hepatic, or renal disease within 6 months prior to first dose
-
Baseline QTcF >480 msec
-
Major surgery or severe trauma within 4 weeks prior to first dose, or planned major surgery during the study
-
Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage
-
History of significant bleeding disorders or recent major bleeding events
-
Clinically significant gastrointestinal conditions, including recent perforation, fistula, obstruction, or active bleeding
-
Active, uncontrolled, or symptomatic infection, including:
- Active TB
- Active hepatitis B or C
- Uncontrolled HIV infection
-
History of immunodeficiency
-
Severe hypersensitivity or allergic reactions to study intervention components or monoclonal antibodies
-
Psychiatric illness or medical condition, including recent suicidal ideation or behavior, that may increase risk or interfere with study participation
-
Prior anti-angiogenic therapy or other prohibited anti-tumor or immunomodulatory therapies per protocol-specified washout periods
-
Use of prohibited concomitant medications, including high-dose systemic corticosteroids, certain anticoagulants, or live vaccines within protocol-specified timeframes
-
Recent participation in another investigational study (within 30 days or 5 half-lives, whichever is longer)
-
Pregnant or breastfeeding participants, or unwillingness to comply with contraception requirements
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: PF-08634404
Participants will receive PF-08634404 in combination with chemotherapy intravenously, followed by maintenance therapy with PF-08634404. |
Injection for intravenous use Concentrate for solution for infusion
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Confirmed Objective Response Rate (ORR) as assessed by investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Tijdsspanne: From start of treatment until first documented CR or PR (approximately maximum up to 1 years)
|
Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) is observed as best overall response. ORR using RECIST v1.1 as assessed by investigator. |
From start of treatment until first documented CR or PR (approximately maximum up to 1 years)
|
|
Number of Participants with Adverse Events (AEs)
Tijdsspanne: Up to 90 days after the last dose of treatment
|
Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Up to 90 days after the last dose of treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidentie van antilichaam tegen geneesmiddel gericht op PF-08634404
Tijdsspanne: Tot 37 dagen na de laatste dosis van de behandeling
|
Tot 37 dagen na de laatste dosis van de behandeling
|
|
|
Farmacokinetiek: Predose en postdose serumconcentraties van PF-08634404
Tijdsspanne: Tot 37 dagen na de laatste dosis behandeling
|
Tot 37 dagen na de laatste dosis behandeling
|
|
|
Progression Free Survival (PFS) as assessed by investigator based on RECIST v1.1
Tijdsspanne: Up to approximately 2 years after completion of study treatment of last study participant
|
PFS is defined as the time from the date of randomization to the date of first documented disease progression, per RECIST v1.1, or death to any cause, whichever occurs first |
Up to approximately 2 years after completion of study treatment of last study participant
|
|
Number of participants with Laboratory abnormalities
Tijdsspanne: Up to 90 days after the last dose of treatment
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. |
Up to 90 days after the last dose of treatment
|
|
Duration of Response (DOR) as assessed by investigator based on RECIST v1.1
Tijdsspanne: Up to approximately 2 years after completion of study treatment of last study participant
|
DOR is defined as the time from the first documentation of objective response (CR or PR) to the date of first documentation of disease progression (PD) or death due to any cause. |
Up to approximately 2 years after completion of study treatment of last study participant
|
|
Overall Survival (OS)
Tijdsspanne: Up to approximately 2 years after completion of study treatment of last study participant
|
OS is defined as the time from the date of randomization to the date of death due to any cause. OS is secondary outcome measure in Phase 2 portion of the study. |
Up to approximately 2 years after completion of study treatment of last study participant
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Pfizer CT.gov Call Center, Pfizer
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- C6461014
- 2025-524686-24-00 (Register-ID: CTIS (EU))
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .